• 1
    Instituto Nacional de Estadística. INEbase: padrón municipal 2011. 2012.
  • 2
    Ministerio de Sanidad y Servicios Sociales e Igualdad. Vigilancia Epidemiológica del VIH/SIDA en España. Actualización 30 de junio de 2011. 2011 Jun 30.
  • 3
    del Amo J, Likatavicius G, Perez-Cachafeiro S et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999–2006. Eur J Public Health 2011; 21: 620626.
  • 4
    European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe. 2010.
  • 5
    del Amo J, Broring G, Hamers FF, Infuso A, Fenton K. Monitoring HIV/AIDS in Europe's migrant communities and ethnic minorities. AIDS 2004; 18: 18671873.
  • 6
    Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS 2003; 17: 283290.
  • 7
    Burns FM, Fakoya AO, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001; 15: 24532455.
  • 8
    Zoufaly A, An der Heiden M, Marcus U et al. Late presentation for HIV diagnosis and care in Germany. HIV Med 2012; 13: 172181.
  • 9
    Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35: 15411548.
  • 10
    Blaxhult A, Mocroft A, Phillips A et al. Does European or non-European origin influence health care and prognosis for HIV patients in Europe? The EuroSIDA Study Group. HIV Med 1999; 1: 29.
  • 11
    Nellen JF, Wit FW, De WF, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004; 36: 943950.
  • 12
    Staehelin C, Rickenbach M, Low N et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17: 22372244.
  • 13
    Jarrin I, Pantazis N, Gill MJ et al. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis 2012; 54: 111118.
  • 14
    Breton G, Lewden C, Spire B et al. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France. HIV Med 2007; 8: 164170.
  • 15
    del Amo J, Petruckevitch A, Phillips A et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12: 12031209.
  • 16
    Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 11391146.
  • 17
    Muller V, von Wyl V, Yerly S et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS 2009; 23: 12691276.
  • 18
    Caro-Murillo AM, Castilla J, Perez-Hoyos S et al. [Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin 2007; 25: 2331.
  • 19
    Sobrino-Vegas P, Gutierrez F, Berenguer J et al. [The cohort of the spanish hiv research network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin 2011; 29: 645653.
  • 20
    Antinori A, Coenen T, Costagiola D et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 6164.
  • 21
    Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224230.
  • 22
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496509.
  • 23
    D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9: 15011515.
  • 24
    Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550560.
  • 25
    Caro-Murillo AM, Gutierrez F, Manuel RJ et al. [HIV infection in immigrants in Spain: epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004–2006)]. Enferm Infecc Microbiol Clin 2009; 27: 380388.
  • 26
    Perez-Molina JA, Pulido Ortega F. Evaluación del impacto del nuevo marco legal sanitario sobre los inmigrantes en situación irregular en España: el caso de la infección por el virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin 2012; 30: 472478.
  • 27
    Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A 2001; 98: 60626067.
  • 28
    Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008). J Int AIDS Soc 2009; 12: 11.
  • 29
    Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008; 10: 212223.
  • 30
    Yebra G, de Mulder M, Perez-Elias MJ et al. Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS ONE 2011; 6: e26757.
  • 31
    Garcia F, Perez-Cachafeiro S, Guillot V et al. Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS). Antiviral Res 2011; 91: 150153.
  • 32
    Eller LA, Eller MA, Ouma B et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS ONE 2008; 3: e3919.
  • 33
    Ngowi BJ, Mfinanga SG, Bruun JN, Morkve O. Immunohaematological reference values in human immunodeficiency virus-negative adolescent and adults in rural northern Tanzania. BMC Infect Dis 2009; 9: 1.
  • 34
    Stohr W, Back D, Dunn D et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675685.
  • 35
    Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39: 537544.
  • 36
    de Arellano ER, Benito JM, Soriano V, Lopez M, Holguin A. Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23: 891894.
  • 37
    Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, Ethnicity B-W. race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008; 47: 441448.
  • 38
    Sumari-de BI, Sprangers MA, Prins JM, Nieuwkerk PT. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav 2012; 16: 16811689.
  • 39
    Bocket L, Cheret A, uffic-Burban S et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10: 247254.
  • 40
    Diaz deQuijano E, Brugal MT, Pasarin MI, Galdos-Tanguis H, Cayla J, Borrell C. [Influence of social inequality, social unrest and extreme poverty on tuberculosis morbidity in the City of Barcelona]. Rev Esp Salud Publica 2001; 75: 517527.
  • 41
    Diez M, Diaz A, Bleda MJ et al. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis 2007; 11: 11961202.
  • 42
    Martin V, Garcia OP, Orcau A, Cayla JA. Factors associated with tuberculosis as an AIDS-defining disease in an immigration setting. J Epidemiol 2011; 21: 108113.
  • 43
    Malmusi D, Borrell C, Benach J. Migration-related health inequalities: showing the complex interactions between gender, social class and place of origin. Soc Sci Med 2010; 71: 16101619.
  • 44
    Razum O, Zeeb H, Rohrmann S. The ‘healthy migrant effect’ – not merely a fallacy of inaccurate denominator figures. Int J Epidemiol 2000; 29: 191192.
  • 45
    Llacer A, Zunzunegui MV, del Amo J, Mazarrasa L, Bolumar F. The contribution of a gender perspective to the understanding of migrants' health. J Epidemiol Community Health 2007; 61 (Suppl 2): ii4i10.
  • 46
    Monge S, del Romero J, Rodriguez C et al. [Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986–2009).]. Enferm Infecc Microbiol Clin 2012; 30: 117123.
  • 47
    Sobrino-Vegas P, Rodriguez-Urrego J, Berenguer J et al. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther 2012; 17: 18.
  • 48
    Monge S, Jarrin I, Perez-Hoyos S et al. Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain. Sex Transm Infect 2011; 87: 571576.
  • 49
    Thierfelder C, Weber R, Elzi L et al. Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study(*). HIV Med 2012; 13: 118126.
  • 50
    Sobrino-Vegas P, Perez-Hoyos S, Geskus R et al. Imputation of the date of HIV seroconversion in a cohort of seroprevalent subjects: implications for analysis of late HIV diagnosis. AIDS Res Treat 2012; 2012: 725412.